Cytodyn Inc (Cytodyn) is a biotechnology company. It focused on developing treatments in the areas of human immunodeficiency virus, cancer, immunology, and novel coronavirus disease corvid 19. The company provides treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab belongs to a class of HIV therapies known as entry inhibitors which block HIV from entering and infecting specific cells. CytoDyn uses prostate diagnostic tests to determine the outcomes of patients diagnosed with prostate cancer. It works in collaboration with pharmaceutical and biotechnology companies to develop its products. The company has an operational presence in Florida, the US. Cytodyn is headquartered in Vancouver, Washington, the US.
Cytodyn Inc premium industry data and analytics
Products and Services
Products |
---|
Product: |
Leronlimab |
Competitor Comparison
Key Parameters | Cytodyn Inc | F. Hoffmann-La Roche Ltd | Merck & Co Inc | AbbVie Inc | Celgene Corp |
---|---|---|---|---|---|
Headquarters | United States of America | Switzerland | United States of America | United States of America | United States of America |
City | Vancouver | Basel | Kenilworth | North Chicago | Summit |
State/Province | Washington | - | New Jersey | Illinois | New Jersey |
No. of Employees | 12 | 103,605 | 72,000 | 50,000 | - |
Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Tanya Durkee Urbach | Chairman | Executive Board | - | 54 |
Jacob Lalezari M.D | Chief Executive Officer | Senior Management | 2024 | - |
Nitya G Ray | Head - Process Sciences; Chief Operating Officer; Chief Technology Officer | Senior Management | 2021 | 69 |
Melissa Palmer | Chief Medical Officer | Senior Management | 2023 | - |
Cyrus Arman | President | Senior Management | 2022 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward